Daxor (NASDAQ:DXR) Stock Price Down 0.9% – What’s Next?

Daxor Corporation (NASDAQ:DXR)’s stock price traded down 0.9% during mid-day trading on Thursday . The stock traded as low as $10.48 and last traded at $10.39. 314 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 1,593 shares. The stock had previously closed at $10.48.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Daxor presently has a consensus rating of “Moderate Buy”.

Daxor Price Performance

The stock has a 50-day moving average of $10.37 and a two-hundred day moving average of $10.86.

Institutional Investors Weigh In On Daxor

A number of institutional investors have recently made changes to their positions in DXR. Aristides Capital LLC purchased a new stake in shares of Daxor in the 1st quarter valued at $403,000. Crescent Grove Advisors LLC purchased a new position in Daxor in the 1st quarter worth $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Daxor in the first quarter worth $245,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Daxor in the fourth quarter worth $184,000. Finally, Osaic Holdings Inc. purchased a new stake in Daxor during the second quarter valued at about $86,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.